The Commons

Wexford Science & Technology

Conversations featuring researchers, innovators, artists, entrepreneurs, community builders, and thought leaders who are improving the human condition in their own backyard and across the globe.

  1. 20h ago

    The Infrastructure Behind Bringing New Therapies to Market: A Conversation with Melissa Marlowe

    The promise of cell and gene therapy is extraordinary. But between a scientific breakthrough and a patient receiving a potentially life-changing treatment lies one of the most complex, precise, and largely invisible networks in healthcare. Recorded live from the BIO International Convention, host Tom Osha sits down with Melissa Marlow, Vice President of Clinical Services and Biotherapies Lab at Vitalant, to explore the infrastructure behind advanced cell therapies and why that infrastructure is critical to expanding patient access. With roots stretching back to a Phoenix blood bank founded more than 80 years ago, Vitalant has built a national network capable of supporting the collection, handling, storage, and delivery of increasingly complex therapies. Melissa takes us behind the scenes of that network, where cells may need to be stored below -150 degrees Celsius, timing is measured in critical windows, and a single patient therapy can touch more than 100 people on its journey from collection to manufacturing and back to the patient. Unlike a traditional pharmaceutical product, many of today's cell therapies are autologous, created from a patient's own cells specifically for that patient. There is no replacement batch sitting on a shelf. Every product is truly one of a kind. Tom and Melissa also discuss the next frontier: moving therapies like CAR-T beyond treatments of last resort and expanding access to patients outside the nation's largest academic medical centers. It's a conversation about science, logistics, culture, and the remarkable human infrastructure required to turn breakthrough medicine into patient care.

  2. Jul 2

    Innovation Begins With Listening: Leith Martin Discuss NSF I-Corps Program and Commercialization for Innovators

    Scientific discovery is only the beginning. The real challenge is transforming breakthrough research into products and companies that improve lives. Recorded live at BIO, this episode of The Commons features Leith Martin, Executive Director of the Pacific Desert Innovation Hub for NSF I-Corps, a program that is reshaping how researchers approach innovation and entrepreneurship across the Southwest.  He is also Executive Director of the Troesh Center for Entrepreneurship and Innovation in the Lee Business School at UNLV, where he oversees entrepreneurship programs and the academic entrepreneurship curriculum. Originally developed by the National Science Foundation, I-Corps has helped thousands of scientists and engineers learn a deceptively simple lesson: before building a company, you have to deeply understand the problem you're trying to solve. Through customer discovery, market validation, and entrepreneurial training, researchers learn to test assumptions, engage potential users, and refine their ideas long before launching a startup. In our conversation, Leith explains why some of the world's most promising technologies never reach the marketplace, how I-Corps is helping bridge the gap between discovery and commercialization, and why entrepreneurial thinking has become an essential skill for today's research community. We also discuss the role programs like the Pacific Desert Innovation Hub play in strengthening regional innovation ecosystems and accelerating the translation of research into economic and societal impact. Whether you're a scientist, entrepreneur, investor, or simply interested in how great ideas become real-world solutions, this conversation offers valuable lessons about the future of innovation.

  3. Jun 12

    How Arizona Built a Bioscience Economy at State Scale: A Conversation with Mary O'Reilly

    When people talk about Arizona's emergence as a bioscience leader, the conversation often focuses on Phoenix. But the state's success story is much larger than any single city. In this episode of The Commons, host Thomas Osha welcomes Mary O'Reilly of the Flinn Foundation for a discussion about the Arizona Bioscience Roadmap and the unique role it has played in advancing innovation and economic development across the entire state. For more than two decades, the Roadmap has provided a shared framework for strengthening Arizona's bioscience sector through strategic investments, collaborative partnerships, talent development, research growth, and commercialization. Unlike many economic development initiatives that focus on a single metropolitan area, Arizona's approach has sought to connect assets and opportunities across the state, aligning universities, healthcare systems, research institutions, entrepreneurs, industry leaders, and policymakers around a common vision. In this conversation, O'Reilly explores how the Roadmap was developed, why it has endured through changing economic and political environments, and how it continues to serve as a catalyst for statewide collaboration. She discusses the measurable impact the strategy has had on research capacity, workforce development, startup formation, healthcare innovation, and Arizona's growing reputation as a center for bioscience and technology-driven growth. The discussion also examines a broader question facing regions throughout the world: how can communities sustain a long-term innovation strategy that extends beyond individual projects, leaders, or election cycles? As The Commons prepares to broadcast from the Arizona Pavilion at the BIO International Convention in San Diego, this episode offers an important perspective on the value of statewide thinking and the power of patient, coordinated leadership.

  4. Jun 12

    Innovating by Design: Matt Ellsworth on Arizona's Bioscience Roadmap

    What does it take to build a world-class bioscience ecosystem? While many regions aspire to become centers of innovation, few have sustained a coordinated strategy long enough to produce transformative results. Arizona is one of the exceptions. In this episode of The Commons, host Thomas Osha is joined by Matt Ellsworth, Chief Operating Officer of the Flinn Foundation, for a conversation about the Arizona Bioscience Roadmap—one of the nation's most enduring and influential regional innovation strategies. Developed more than two decades ago, the Roadmap was created to help Arizona diversify its economy and strengthen its position in the life sciences. Since then, it has served as a guiding framework for collaboration among universities, healthcare systems, research institutions, entrepreneurs, industry leaders, philanthropies, and government partners across the state. The results have been significant. Arizona has emerged as a growing center for bioscience research, commercialization, healthcare innovation, and talent development, with the Phoenix Bioscience Core becoming one of the most visible manifestations of that progress. In this discussion, Ellsworth reflects on the origins of the Roadmap, the leadership and partnerships that have sustained it through multiple economic cycles, and the lessons learned from more than 20 years of ecosystem building. He also explores how the Roadmap continues to evolve in response to new opportunities in precision medicine, biotechnology, workforce development, and innovation-driven economic growth.

  5. Apr 30

    How Breakthroughs Get Built: A Conversation with Steve Potts

    In this episode of The Commons, host Thomas Osha sits down with Steve Potts, CEO of Breakthru Medicine, to explore what it actually takes to turn scientific insight into life-changing therapies. With multiple FDA-approved drugs in his track record and a newly closed $60 million Series A, one of the largest early-stage financings in Phoenix’s bioscience ecosystem, Potts brings a rare perspective on building in a field defined by uncertainty, long timelines, and high stakes. The conversation moves beyond the headlines to unpack the mechanics of innovation. Potts shares how experience, judgment, and data come together to identify which ideas have real potential, and which don’t. He explains Breakthru Medicine’s patient-first, tumor-agnostic approach, and the emerging science behind molecular glues, small molecules, and next-generation antibody-drug conjugates. Osha and Potts also step back to examine the broader system: why so many therapies fail, how startups and large pharma play complementary roles, and why new geographies like Phoenix are becoming credible centers of biotech innovation. At its core, this episode is about decision-making under uncertainty—how leaders place bets when the outcomes matter deeply and the answers aren’t clear. For anyone interested in the future of medicine, innovation, or building at the edge of what’s possible, this conversation offers a clear-eyed look at how breakthroughs actually get built.

Trailers

Ratings & Reviews

5
out of 5
4 Ratings

About

Conversations featuring researchers, innovators, artists, entrepreneurs, community builders, and thought leaders who are improving the human condition in their own backyard and across the globe.

You Might Also Like